J Korean Liver Cancer Stud Search

CLOSE


J Liver Cancer > Volume 14(2); 2014 > Article
Journal of the Korean Liver Cancer Study 2014;14(2):120-126.
DOI: https://doi.org/10.17998/jlc.14.2.120    Published online September 30, 2014.
A Case of Achieving Partial Remission with Combination of Radiation Therapy and Sorafenib inChild-Pugh Class B Patients with Hepatocellular Carcinoma with Main Portal Vein Invasion and Lymph Node Metastasis
Sang Youn Hwang1, Seon-Mi Lee1, Jung Woo Im1, Joon Suk Kim1, Sang Bu Ahn2, Eun Kyeong Ji2, Hyun-Cheol Kang3, Cheol-Won Choi3, Gwang-Mo Yang3
1Department of Internal Medicine and Gastrointestinal Cancer Center, Dongnam Institute of Radiological& Medical Sciences, Busan, Korea
2Department of Radiology, Dongnam Institute of Radiological& Medical Sciences, Busan, Korea
3Department of Radiation Oncology, Dongnam Institute of Radiological& Medical Sciences, Busan, Korea
Correspondence:  Sang Youn Hwang,
Email: mongmani@hanmail.net
Copyright ©2014 by The Korean Liver Cancer Association
Abstract
Reserved liver function is one of the most important determinants of survivial in advanced hepatocellular carcinoma (HCC). Especially in cirrhotic patient with decompensated liver function, sorafenib for HCC with main portal vein invasion have limited efficacy and survival benefit. Therefore many clinicians or centers still try locoregional therapy (LRT) such as transarterial chemoembolization (TACE), radiation therapy (RT), or combination with LRT and sorafenib in this situation. However this multidisciplinary approach may increase treatment related toxicity such as liver failure, etc. Recently, studies for combination of RT and sorafenib for HCC with portal vein invasion have been tried and reported not only better therapeutic efficacy, but also more hepatic toxicity.Based on above suggestions, we herein offer our experience of a patient that although achieved survival gain via partial remission of intrahepatic tumor and main portal vein thrombosis and metastatic lymph node by combination therapy of RT and sorafenib, finally expired due to hepatictoxicity. Further study, maybe regarding a combination of locoregional and systemic therapy, is necessary on how to manage decompenstated cirrhotic patients with HCC with main portal vein invasion. (J Liver Cancer 2014;14:120-126)
Key Words: Hepatocellular carcinoma; Decompenstation; Portal vein invasion; Radiation therapy; Sorafenib; Combination therapy; Toxicity
NULL


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
1527 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2019 by The Korean Liver Cancer Association. All rights reserved.

Developed in M2community

Close layer
prev next